John Paulson bought $312.5M of Bausch Health Companies (BHC)
Executed Aug 14 2025, disclosed Aug 15 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Aug 14 2025), the stock returned -1.2% (delay-adjusted); from the execution session (Aug 14 2025), -1.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
John Paulson (Director) filed 4 Form 4 reports in the past 24 months (4 purchases, 0 sales), most often in Bausch Health Companies Inc. (BHC). Across 4 priced purchase filings, the average 21-session return was +17.6% from execution and +8.1% from disclosure (delay-adjusted; derived). The largest single filing was $312.5M of BHC (34,721,118 sh × $9.00, as filed), executed Aug 14 2025.
Healthcare · Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→3,243,049 sh across 3 lots
Exec Aug 11 2025
Filed Aug 13 2025 · 6:51 PM ET BHCPURCHASE Bausch Health Companies Inc. $21.2M
3,564,059 sh × $5.94
Exec Jun 13 2025
Filed Jun 17 2025 · 5:30 PM ET BHCPURCHASE Bausch Health Companies Inc. $14.7M
2,788,608 sh across 3 lots
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET